PALOMA-3 Trial Design
PALOMA-3 included women with varying sites of disease and prior treatment histories, and regardless of menopausal status.*
No significant differences in the clinical and pathological characteristics of the patients were identified between the 2 treatment groups (IBRANCE + fulvestrant n=347; placebo + fulvestrant n=174).
Selected baseline characteristics for the IBRANCE arm